Printer Friendly

Dust mite allergy vaccine given clinical trial approval in Spain.

M2 EQUITYBITES-February 15, 2017-Dust mite allergy vaccine given clinical trial approval in Spain

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Allergy Therapeutics (AIM:AGY) has been granted clinical trial approval in Spain for its Phase I AM101 clinical study. The study will evaluate the safety concerns of the adjuvant, modified house dust mite allergy vaccine, a press release published on Pharmiweb reported on Wednesday.

Allergy Therapeutics is a fully integrated specialty pharmaceutical company that focuses on generating vaccines for allergies. The Phase I study will examine the safety and efficacy of Acarovac MPL (monophosphoryl lipid A) has received Clinical Trial Application (CTA) approval in Spain.

Dust mites are a pervasive cause of perennial allergic rhinitis and allergic asthma. The company is now able to start the clinical trials immediately to begin their investigation of the safety and tolerability of the two potential dose regimens. Both treatments will include a two-to-four week "dosing up" stage, however, one will be altered in the later maintenance phase.

Manuel Llobet, chief executive officer of Allergy Therapeutics, welcomed the news, commenting: "we aim to improve both safety and efficacy for the thousands of patients who suffer year-round due to house dust mite allergy. Acarovac Quattro will provide convenience to our patients and doctors and more efficient pharmacoeconomics.

"Effectively, the dosing regime in Acarovac Quattro has the potential to improve the convenience, adherence and compliance that is essential for a successful treatment, and builds on the acceptance of the existing Acarovac Plus platform."

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:4EUSP
Date:Feb 15, 2017
Words:259
Previous Article:DynaEnergetics to initiate price increase in the Americas on or after 1 March 2017.
Next Article:Concordia Maritime signs USD36m sale & leaseback agreement for the IMOIIMAX tanker Stena Important.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters